The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
FDA grants venetoclax approval for the treatment of newly diagnosed acute myeloid leukemia
On 21 November 2018, the US Food and Drug Administration (FDA) granted accelerated approval to venetoclax, an oral inhibitor of BCL-2, in combination with azacitidine, decitabine or low-dose cytarabine (LDAC) for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.1
The approval for venetoclax was based on data obtained from two phase Ib/II open-label non-randomized trials (M14-358 and M14-387 study) in patients with newly-diagnosed AML who were age 75 years or older or had comorbidities that precluded the use of intensive induction chemotherapy. In the M14-358, the combination of venetoclax with azacitidine (n = 67) or decitabine (n = 13) led to a complete remission (CR) rate of 37% and a CR with partial hematological recovery (CRh) rate of 24%.2 More results of this study are reported here.
In the M14-387 study, the combination of venetoclax with LDAC demonstrated a clinically durable activity in elderly patients with newly diagnosed AML who are eligible for intensive chemotherapy. Venetoclax and LDAC combination led to a CR rate of 21% and a CRh rate of 21% in elderly patients in newly diagnosed AML patients who are ineligible for intensive chemotherapy.3 More results from this study are reported here.
The FDA approved this indication for venetoclax under accelerated approval based on response rates. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. About the approval for venetoclax, Daniel A. Pollyea, from the University of Colorado, Denver, US, said “many of my patients are ineligible for the intensive treatment for AML, which typically involves intensive chemotherapy. Only a minority of AML patients older than 60 are able to tolerate the standard chemotherapy required to achieve optimal results. Having a new medicine to treat AML is encouraging for my patients and their families. Venetoclax approval is a true breakthrough for AML patients ineligible for intensive chemotherapy."1
References